BriaCell Therapeutics
Chart
briacell therapeutic Overview
BriaCell Therapeutics is pioneering a new class of off-the-shelf personalized immunotherapies, exploring the potential to double overall survival in advanced breast cancer.
BriaCell Therapeutics (TSX:BCT,NASDAQ:BCTX) is a clinical-stage immuno-oncology company dedicated to transforming cancer care through the development of new classes of targeted immunotherapies. Its lead drug candidate is the Bria-IMT Cell Therapy, an off-the-shelf therapy designed to activate a patient’s immune system to target cancer cells without harming other cells. Bria-IMT™ is currently the subject of a pivotal Phase 3 study, under Fast Track designation, aimed at securing full approval from the US Food and Drug Administration (FDA).
The company is also advancing the Bria-OTS™ and Bria-OTS+™, a personalized off-the-shelf platform that aims to provide an innovative way to treat breast cancer and eventually expand to prostate and lung cancer and melanoma therapies.
BriaCell’s strategy is built on clinical validation and capital efficiency, with its seasoned team of scientists and clinicians having a combined record of 20 drug and device approvals.
Detailed Quote
Dr. William V. Williams – President & CEO
With over 35 years of experience, Dr. Williams has spearheaded numerous successful clinical programs. He previously served as the Head of Rheumatology Research at the University of Pennsylvania, where he led a major research program in receptor biology and brought novel DNA vaccines to the clinic for the treatment of cutaneous T cell lymphoma. As VP of Exploratory Development at Incyte Corporation from 2005 to 2016, he facilitated the entry of over 20 compounds, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant).
Dr. Giuseppe Del Priore – Chief Medical Officer
Dr. Del Priore brings extensive experience in gynecologic oncology and clinical trial management. Recognized as a Key Opinion Leader (KOL) in oncology with several patents to his name, he is also an author and was listed among the “Best Doctors” by the U.S. News & World Report. He oversees the clinical development of BriaCell’s lead candidates and ensures the rigorous execution of the pivotal Phase 3 program.
Miguel A. Lopez-Lago – Chief Scientific Officer
Dr. Lopez-Lago is a veteran cancer scientist with over 20 years of experience at Memorial Sloan-Kettering Cancer Center (MSKCC), specializing in tumor biology and the mechanisms of metastasis. His recent research focuses on the tumor immune-microenvironment and the development of advanced immunotherapies, including CAR T cell technologies for thoracic cancers.
*Disclaimer: This profile is sponsored by BriaCell Therapeutics ( TSX:BCT ). This profile provides information which was sourced by the Investing News Network (INN) and approved by BriaCell Therapeutics in order to help investors learn more about the company. BriaCell Therapeutics is a client of INN. The company's campaign fees pay for INN to create and update this profile.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
This profile contains forward-looking information, including statements regarding planned activities, timelines, business objectives, and market conditions. Forward-looking information is based on assumptions and is subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. Readers should not place undue reliance on forward-looking information, which reflects the views of the profiled company as of the date of this profile and is not updated by INN.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with BriaCell Therapeutics and seek advice from a qualified investment advisor.